FDA Panel Rejects MDMA for PTSD Therapy, Citing Concerns
TL;DR Summary
An FDA advisory panel voted against the approval of MDMA for treating PTSD, citing unproven efficacy and safety concerns. Despite promising results from clinical trials, issues such as the inability to blind studies and potential biases led to the decision. The FDA will make a final decision in August.
- MDMA therapy for PTSD rejected by FDA panel Nature.com
- A big problem for psychedelic medicine - POLITICO POLITICO
- Psychedelics Are Challenging the Scientific Gold Standard The Atlantic
- FDA advisors reject MDMA as treatment for PTSD : Shots - Health News NPR
- Ecstasy's Rebuff as PTSD Therapy Exposes Sloppy Processes at FDA Bloomberg
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
5 min
vs 5 min read
Condensed
95%
961 → 49 words
Want the full story? Read the original article
Read on Nature.com